1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • López-Robles J, Mitjavila M, Jimenez-Fonseca P, Marín-Melero I, Belló P, Pubul V, Garcia-Burillo A, Hernando J, Llana B, Ardila J, Arbizu J, Valverde R, Velasco M, Castellón M, Alonso-Gordoa T, García-Cañamaque L, Cano JM, Tabuenca MJ, Riesco MC, Custodio AB, Piñeiro A, Balaguer-Muñoz D, Nevares M, Carmona-Bayonas A.

    Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

    ONCOLOGIST . 31(7): .

    [doi:10.1093/oncolo/oyag231]

  • Barretina-Ginesta MP, Redondo A, Cortés-Salgado A, Madariaga A, Pérez-Mies B, Sancho L, Valls-Masot L, Domínguez M, González-Martín A.

    Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(6): 104684-104684. Number of citations: 3

    [doi:10.1016/j.ijgc.2026.104684]

  • Molina-Cerrillo J, Sierra-Ramirez A, López-Aceituno JL, Méndez-Pertuz M, Alonso-Gordoa T, Linnebacher M, Santoni M, Fernandez-Marcos PJ, Grande E.

    A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.

    DRUGS IN R&D . 26(2): 155-167.

    [doi:10.1007/s40268-026-00544-x]

  • Peg V, Burgués O, Ruiz I, Carcedo D, García JF, Monzón Naranjo MA, Tonic I, Echeverría T, Segura A, Alfonsín N, Fiaño MC, Pérez-Mies B.

    A Decade of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer in Spain: A Comprehensive Real-World Data Analysis (2013-2023).

    Clinical Breast Cancer . 26(6): .

    [doi:10.1016/j.clbc.2026.04.009]

  • Alonso-Gordoa T, Fernández-Calvo O, García-Carbonero I, Álvarez-Rodríguez S, Sánchez-Escribano R, Anguera G, González-Del-Alba A, Gallardo E, Cacho D, Vidal N, Pinto Á, Perezagua C, Zafra-Poves M, Cassinello J, Rodriguez-Vida A, López-Campos F, Vázquez-Estévez S.

    Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter study.

    Clinical & Translational Oncology . 28(6): 2360-2368.

    [doi:10.1007/s12094-025-04174-8]

  • Garrigós L, Ruiz-Borrego M, Pérez-García JM, Guerrero-Zotano A, Cortés-Salgado A, Kuemmel S, Colleoni M, Reboredo-Rendo C, Bermejo B, Blancas I, Gavila J, Fabi A, Morales C, Stradella A, Carañana V, Martínez-de Dueñas E, Albacar C, Ballesteros-Cidras O, Martrat G, Iacobucci S, Boix O, Berenguer-Molins P, Alcalá-López D, Cortés J, Llombart-Cussac A.

    A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

    ANNALS OF ONCOLOGY . 37(6): 837-848.

    [doi:10.1016/j.annonc.2026.01.013]

  • Sánchez Gómez R, Pérez-Míes B, Palacios J, Moreno Bueno G, Calvo I, Solorzano JL, Neria F, Fernandez-Abad M, González-Martínez S, García-Estevez L.

    Association of Body Mass Index with Tumor-Infiltrating Lymphocytes and Treatment Response in Early HER2-Positive Breast Cancer.

    International Journal of Womens Health . 18: 596039-596039.

    [doi:10.2147/IJWH.S596039]

  • A AC, H AC, V RB, I CB, I RC, H P, J DJ, P I.

    Assessment of intratumoral collagen in pituitary neuroendocrine tumors (pituitary adenomas/PitNets) via digital pathology and its correlation with intraoperative consistency.

    Pituitary . 29(3): .

    [doi:10.1007/s11102-026-01703-8]

  • Rodríguez-Villena A, Schmülling UCV, Zapata IV, Rivas-Fidalgo S, Gión-Cortés M, López-Rodríguez MJ, Carretero-Barrio I, Palacios J, Pérez-Mies B.

    Implementation of a Multidisciplinary Protocol for the Safe Handling of Iodine-125 Radioactive Seeds in the Pathology Laboratory.

    International Journal of Breast Cancer . 2026: 3962099-3962099.

    [doi:10.1155/ijbc/3962099]

  • O'Shaughnessy J, Bidard FC, Neven P, Casalnuovo ML, Aftimos P, Saura C, Harbeck N, Carey LA, Curigliano G, Garcia-Saenz JA, Abad MF, Paula L, Park YH, Ozyilkan O, Munoz M, Barrett E, Cao S, Chawla A, Jhaveri KL.

    Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.

    npj Breast Cancer . 12(1): .

    [doi:10.1038/s41523-026-00950-z]

  • Perez-Gracia JL, Mellado B, Hansen AR, Alonso-Gordoa T, Gomez-Roca C, Løvendahl Eefsen R, Negrier S, Suárez C, Lee JL, Hussain A, Pedrazzoli P, Moreno V, Rodriguez-Vida A, Sosman JA, Waddell T, Bedke J, Park SH, Sznol M, Spychaj L, Andersson E, Julien-Laferriere A, Cheng WY, Watson C, Silva AP, Heichinger C, Staedler N, Sleiman N, Dejardin D, Boetsch C, Evers S, Vardar T, Ardeshir-Tandon C, Dorado Pérez J, Charo J, Keshelava N, Kraxner A, Teichgräber V, Powles T.

    Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

    Journal for ImmunoTherapy of Cancer . 14(4): .

    [doi:10.1136/jitc-2025-012466]

  • Capdevila J, Hernando J, Molina-Cerillo J, Plana Serrahima M, Taberna Sanz M, Castelo B, Álvarez-Escolá C, Carmona-Bayonas A, Ballester Navarro I, Iglesias L, Bover M, Garcia-Alvarez A, Lavernia J, Yayá Tur R, Ruiz S, Baste N, Lorenzo-Lorenzo I, Sanchez-Hernandez A, Sanz-Garcia E, Marquina G, Nuciforo P, Elguero B, Grande E, Alonso-Gordoa T.

    Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

    Nature Communications . 17(1): .

    [doi:10.1038/s41467-026-71155-y]

  • Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, Hernando J, Rodrigo-Calvo MT, Jimenez-Fonseca P, Quiceno-Arias HD, Lorenzo-Lorenzo I, Bella-Cueto MR, Iglesias C, Cameselle-Teijeiro JM, Capdevila J.

    SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

    Revista Espanola de Patologia . 59(2): 100859-100859. Number of citations: 2

    [doi:10.1016/j.patol.2026.100859]

  • Moreno-Moreno E, Caniego-Casas T, Ruz-Caracuel I, Carretero-Barrio I, Cabezas-López E, Cortés-Salgado A, Mendiola M, Redondo A, Muriel A, Hardisson D, Palacios J, Pérez-Mies B.

    MDM4 amplification as a potential predictor of risk of recurrence in early-stage low-grade endometrial carcinoma.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(4): 104563-104563.

    [doi:10.1016/j.ijgc.2026.104563]

  • Barretina-Ginesta MP, Madariaga A, Gil-Martín M, Ramchandani A, Pardo M, Sanchez-Heras AB, Churruca C, Guerra-Alia EM, Madroñal C, Fernandez-Plana J, Herrero A, Dotor E, Esteban C, Quindós-Varela M, Romeo M, Gost E, Bermejo MJ, Fernandez-Chacón C, Ferrer N, Gomez-Raposo C, Tort SC, Eichbaum M, Sehouli J, Woopen H.

    Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(4): 102758-102758.

    [doi:10.1016/j.ijgc.2025.102758]

  • Lázaro-Navas I, Mur-Molina B, Villalobos-Baeza EB, Cortés-Salgado A, Pailos RH, Díaz-Soto EM, Fernández-Pardo TE, López-González L, Valcárcel-Linares D.

    Effectiveness of radiofrequency therapy combined with pelvic floor muscle training in breast cancer survivors with genitourinary syndrome of menopause: a study protocol.

    European Journal of Obstetrics & Gynecology and Reproductive Biology . 320: 115010-115010.

    [doi:10.1016/j.ejogrb.2026.115010]

  • Garcia-Carbonero R, Benavent M, Jimenez-Fonseca P, Alonso-Gordoa T, Teulé A, Custodio A, Tafuto S, La Casta A, Spada F, López C, Ibrahim T, Iranzo V, García-Alfonso P, González-Flores E, Villanueva Silva MJ, Grande E, Panzuto F, Crespo G, Navarro M, Castellano D, Hernando J, Morales-Herrero R, Iglesias Álvarez G, Soldevilla B, Capdevila J.

    Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

    JOURNAL OF CLINICAL ONCOLOGY . 44(9): 774-786. Number of citations: 5

    [doi:10.1200/JCO-25-01808]

  • Tolosa P, García-Fructuoso I, Pascual T, Martínez-Sáez O, Cejalvo JM, Servitja S, Fernández Abad M, Benitez Fuentes JD, Brasó-Maristany F, Sanfeliu E, Lema L, Ruano Y, Parrilla L, Roncero AM, Cobos MÁ, Díaz I, Centelles López KA, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.

    Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

    BREAST CANCER RESEARCH AND TREATMENT . 216(2): .

    [doi:10.1007/s10549-026-07931-7]